Di yu pan guan1/18/2024 ![]() ![]() Journal Article: Low-dose IL-2 Treatment Rescues Cognitive Deficits by Repairing the Imbalance Between Treg and Th17 Cells at the Middle Alzheimer’s Disease Stage More recently, he co-led a team to develop VEGF antibodies linked to exosomes derived from regulatory T-cells to treat choroidal neovascularization (Nature Biomedical Engineering, 2021) He co-led the clinical study showing that allergen immunotherapy improves defective follicular regulatory T cells in patients with allergic rhinitis (2019, Journal of Allergy and Clinical Immunology). ![]() He co-led the first open-labelled (2016, Nature Medicine) and subsequently randomised controlled clinical trial (2020, Annals of the Rheumatic Diseases) for low-dose IL-2 therapy in lupus. Professor Yu has established a broad collaboration network with clinicians. Also known as precursor exhausted T cells, they respond to immune checkpoint therapy blocking PD-1/PD-L1. Furthermore, he identified that CD8+ Tfc cells control HIV infection in Tfh cells and EBV infection in B cells (2016, Nature Immunology). More recently, he discovered the bioavailability of Tfh-derived IL-21 is essential to control the quality of antibody responses (2023, Science Immunology). He identified the metabolic hormone leptin and the ferroptosis-regulated survival pathway as physiological regulators of Tfh cell function and modulating vaccine response (2021, Nature communications Nature Immunology). He led the research to develop a method to monitor the activity of Tfh cells in humans (2013, Immunity). ![]() He discovered the major molecular mechanism in controlling the differentiation and function of Tfh cells, which include the master transcription factor Bcl6 (2009, Immunity) and Roquin-mediated posttranscriptional regulation (2007, Nature). His findings have profoundly influenced the prevention (vaccination), diagnosis and treatment of autoimmune, infectious diseases and cancer. By revealing their novel functions and regulation. He was the first to identify the CD4+ and CD8+ T cell subsets – follicular helper T (Tfh) and follicular cytotoxic T (Tfc) cells. Professor Yu has made major contributions to T-cell immunobiology. He is an elected Fellow of the Australian Academy of Health and Medical Sciences (FAHMS). In recognition of his ground-breaking research, he has received several major awards from Australian Academy of Science (AAS), Australia Academy of Health and Medical Sciences (AAHMS), the Australia and New Zealand Society for Immunology (ASI), Australian National Health and Medical Research Councial (NHMRC) and International Cytokine & Interferon Society (ICIS). He is a Clarivate Highly Cited Researcher and among the world's top experts in follicular helper T cells. Professor Yu has authored over 100 publications of basic and translational research in immunology, including Nature, Nature Immunology, Nature Medicine, Immunity and Science Immunology. By investigating T cell functional subsets in human health and disease, he innovates "systems immunology" approaches to monitor personal immune status and designs new strategies to treat autoimmune diseases, infection, and cancer by controlling immune pathways. Before joining the University of Queensland, he was a faculty member at Monash University from 2011-2016 and at Australian National University ANU from 2017-2019. He received his PhD from Australian National University in 2007 and postdoctoral training at the Garvan Institute of Medical Research from 2008-2010. Professor Di Yu is a Chair in Paediatric Immunotherapy, Professor of Immunology, Director of Ian Frazer Centre of Children's Immunotherapy Research, and Head of Systems and Translational T-cell Immunology Laboratory (STTIL) at the University of Queensland.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |